IGF-1 LR3 Preclinical

What It Is

IGF-1 LR3 (Long Arginine 3-IGF-1, also written LR3-IGF-1 or LongR³IGF-I) is a synthetic, recombinantly produced protein analog of human insulin-like growth factor-1 (IGF-1) — engineered for substantially extended half-life and reduced binding to IGF-binding proteins (IGFBPs). It is 83 amino acids in length compared to native IGF-1's 70, owing to a 13-amino-acid N-terminal extension (sequence MFPAMPLLSLFVN) and a single substitution at position 3 (glutamic acid → arginine, the "R3" in the name). The combined effect of these modifications: IGFBP-3 binding affinity is reduced approximately 1000-fold relative to native IGF-1, and active circulating half-life is extended from ~10–15 minutes for native IGF-1 to ~20–30 hours for the LR3 form.

IGF-1 LR3 was originally developed in the 1990s as a research reagent for cell culture media — a more stable IGF-1 variant for biotechnology applications including mammalian cell line cultivation, biopharmaceutical production, and laboratory growth-factor supplementation. It is sold by major life-sciences suppliers (BioVision, Sigma-Aldrich, Repligen, GroPep) for these laboratory uses. Its application as an injectable for body composition, muscle growth, and recovery is entirely off-label community use that emerged from the bodybuilding and performance optimization scenes in the 2000s. There has never been a clinical pharmaceutical development program for IGF-1 LR3 itself in humans.

Critically, IGF-1 LR3 is not the same molecule as mecasermin (Increlex), the FDA-approved recombinant human IGF-1 marketed by Ipsen for severe primary IGF-1 deficiency in children. Mecasermin is identical in sequence to native human IGF-1 (70 amino acids, no R3 modification, no N-terminal extension) and has a half-life closer to native IGF-1 — typically requiring twice-daily dosing in pediatric protocols. Mecasermin has rigorous regulatory approval and clinical trial backing; IGF-1 LR3 has neither. Collapsing the two into a single category — a frequent error in optimization-community literature — obscures the very different evidence bases.

The community appeal of IGF-1 LR3 is straightforward: a once-daily SubQ injection produces sustained IGF-1 receptor activation for a full 24 hours, with theoretical hyperphysiologic effects on muscle protein synthesis, cellular proliferation, glucose uptake, and tissue repair. The reality is more complicated: there is essentially no published clinical evidence in healthy human subjects, the hypoglycemia risk is meaningful (IGF-1 has insulin-mimetic activity at IGF-1R and partial cross-reactivity with the insulin receptor), and the GH/IGF-1-axis cancer-promotion concerns that apply to chronic GH-elevating compounds apply more directly here.

Mechanism of Action

IGF-1 LR3 acts on the IGF-1 receptor (IGF-1R) — the same receptor as native IGF-1 — but with a markedly different pharmacokinetic profile due to its escape from IGFBP regulation.

• IGF-1R agonism (primary mechanism) — IGF-1 LR3 binds IGF-1R, a transmembrane receptor tyrosine kinase expressed on essentially all cell types. Receptor activation triggers autophosphorylation, recruitment of insulin receptor substrates (IRS-1/2), activation of PI3K/Akt/mTOR cascade (anabolic signaling), and Ras/MAPK cascade (proliferative signaling). The downstream effects mirror native IGF-1.
• The IGFBP escape — the central pharmacologic difference — Approximately 95–99% of circulating native IGF-1 is bound to one of six IGF-binding proteins (IGFBP-1 through IGFBP-6, dominantly IGFBP-3 in serum). This binding is regulatory: bound IGF-1 is sequestered, has extended circulation but lower receptor accessibility. The R3 substitution and N-terminal extension of LR3 reduce IGFBP-3 binding ~1000-fold. As a result, LR3 circulates predominantly as free protein, accessible to IGF-1R immediately, and is not subject to the homeostatic buffering that native IGF-1 has.
• Extended half-life — Native IGF-1 free half-life is ~10–15 minutes. The IGFBP-3 / acid-labile-subunit (ALS) ternary complex extends total IGF-1 plasma residence to ~12–15 hours, but the free fraction is still short-lived. IGF-1 LR3, escaping this binding, has a free half-life of ~20–30 hours — supporting once-daily dosing.
• PI3K/Akt/mTOR — the anabolic signal — IGF-1R activation drives PI3K/Akt/mTORC1 signaling, which is the central pathway for muscle protein synthesis, cellular growth, and ribosomal biogenesis. mTORC1 activation is the molecular basis for the muscle hypertrophy and tissue repair claims.
• Ras/MAPK — proliferative signal — IGF-1R also activates Ras/Raf/MEK/ERK signaling, driving cellular proliferation, anti-apoptosis, and (in some contexts) cellular differentiation. This is the molecular basis for the muscle-cell hyperplasia hypothesis (creating new muscle cells, not just enlarging existing ones) — though robust in-vivo evidence for hyperplasia in adult human skeletal muscle is contested.
• Insulin receptor cross-reactivity (the hypoglycemia mechanism) — IGF-1R and insulin receptor are structurally related; IGF-1 has measurable but lower-affinity binding to the insulin receptor. At hyperphysiologic LR3 concentrations, sufficient insulin receptor activation occurs to drive measurable glucose uptake into muscle and adipose tissue. This is the mechanism for the well-documented IGF-1 LR3 hypoglycemia risk — particularly when dosed in fasted state.
• Glucose uptake (insulin-like) — IGF-1 LR3 stimulates GLUT-4 translocation in muscle and adipose tissue analogous to insulin, increasing glucose uptake and reducing blood glucose. This is desirable in some contexts (post-workout glucose disposal) but risky in others (fasted state, basal glucose handling).
• Anti-lipolytic in adipose — IGF-1R activation in adipose tissue is anti-lipolytic; chronic elevated IGF-1 may modestly favor fat storage in the absence of caloric deficit. This is opposite to the pop-culture narrative that IGF-1 is "fat-burning."
• Cell-type-specific effects — Skeletal muscle: anabolic, hypertrophic. Tendon/bone: anabolic, regenerative. Liver: feedback inhibition of GH secretion (long loop). Brain: trophic effects on neurons (basis for neurological IGF-1 research). Each tissue's IGF-1R density and downstream signaling fidelity differs.
• What it does not do — Does not act through GHS-R1a (the ghrelin receptor) — distinct from GHRPs. Does not stimulate endogenous GH release (it suppresses GH via long-loop negative feedback). Does not have selective tissue targeting; affects all IGF-1R-expressing tissues.

What the Research Shows

The research base for IGF-1 LR3 specifically is dominated by cell culture and biopharmaceutical-process applications. Direct human clinical evidence is essentially absent. Native IGF-1 (mecasermin) has substantial human evidence; that evidence does not directly transfer to the LR3 form because of the pharmacokinetic differences.

• Cell culture / bioprocess research base (largest body of work) — IGF-1 LR3 is widely used as a growth factor supplement in mammalian cell culture media for biopharmaceutical production (CHO cell cultures, hybridoma cultures, stem cell maintenance). Its IGFBP-resistance and extended half-life are advantageous in serum-free media formulations. Hundreds of papers reference LR3 in this context.
• Animal hypertrophy studies (cell-line and rodent) — Multiple rodent studies have shown IGF-1 LR3 promotes skeletal muscle hypertrophy, accelerates muscle regeneration after injury, and supports satellite cell activation. Dose-dependent effects on muscle fiber cross-sectional area are reproducible.
• Glucose uptake studies (3T3-L1 adipocytes; PMC5750484) — Comparative work showing IGF-1 LR3 induces dose-dependent glucose uptake in 3T3-L1 adipocytes — demonstrating the insulin-like activity that underpins the hypoglycemia risk.
• Native IGF-1 (mecasermin) human evidence (DOES NOT directly transfer to LR3) — Mecasermin (Increlex) has approval for severe primary IGF-1 deficiency in children based on multi-year clinical trials demonstrating linear growth promotion and metabolic effects. The pediatric protocol is twice-daily SubQ injection of native rhIGF-1 with strict hypoglycemia monitoring. The evidence base is robust for the pediatric IGFD indication. Generalization to adult bodybuilding contexts is not supported.
• Mecasermin in HIV-associated wasting (older studies) — Native rhIGF-1 was investigated for HIV-related wasting; modest signal but not advanced beyond Phase 2/3 in this indication.
• Mecasermin combined with rhGH — Combination protocols have been investigated for additional growth promotion in pediatric severe IGFD; modest additional benefit reported.
• No published human trial of IGF-1 LR3 specifically — A search of ClinicalTrials.gov for "IGF-1 LR3" or "LR3-IGF-1" returns no registered human trials as of April 2026. The optimization community use is entirely off-label and uncontrolled.
• Bodybuilding and athletic-use case reports — anecdotal only — Bodybuilding forums, podcasts, and practitioner reports describe LR3 use for muscle growth, recovery, and lean mass preservation in fat-loss phases. None of this constitutes clinical evidence; selection bias and reporting bias are large.
• Cancer / tumor-promotion theoretical concern — Chronic elevation of IGF-1 is epidemiologically associated with increased risk of certain cancers (colorectal, prostate, breast). IGF-1 LR3, as a sustained-action IGF-1R agonist, presents this concern more directly than transient GH-secretagogue use. The mechanism is biologically plausible: tumor cells express IGF-1R, and IGF-1R activation drives proliferation and resistance to apoptosis.

Human Data

There is no published human trial of IGF-1 LR3 specifically. The closest available human evidence is for mecasermin (native rhIGF-1).

• Mecasermin (native rhIGF-1, FDA-approved as Increlex) — Approved 2005 for severe primary IGF-1 deficiency in children. Multi-year pediatric trials documented linear growth promotion, IGF-1 normalization, and the requirement for strict hypoglycemia precautions (must be administered with food).
• Mecasermin pediatric IGFD trial program (Ipsen / Tercica) — Multi-year trials supporting Increlex approval. Twice-daily SubQ dosing of native rhIGF-1; sustained linear growth response; well-characterized side-effect profile.
• HIV-associated wasting (mecasermin-related) — Investigated in older trials with modest signal; not advanced to approval for this indication.
• Native IGF-1 in adult muscle / aging — Some small studies have evaluated native IGF-1 effects in adult sarcopenia and aging contexts. Modest effects; not clinically transformative.
• No registered human trial of IGF-1 LR3 — A search of ClinicalTrials.gov returns nothing as of April 2026.
• Athletic doping detection studies — Multiple WADA-accredited laboratory papers establishing detection methods for IGF-1 analogs including LR3 in serum and urine. Detection is established and routine.
• Practical implication — Anyone using IGF-1 LR3 is operating entirely outside published controlled human evidence. The threshold for clinician supervision and conservative dosing should be very high.

Dosing from the Literature

No FDA-approved dose exists for IGF-1 LR3. Doses below are from community use and the closely-related mecasermin pediatric protocol. Not medical advice.

Reconstitution & Storage

IGF-1 LR3 is supplied as a lyophilized powder, typically in 1 mg vials.

• Acidic reconstitution required — IGF-1 LR3 is most stable in slightly acidic solution. Some sources recommend reconstituting with acetic-acid-stabilized BAC water rather than plain BAC water. The Increlex (mecasermin) approved formulation uses sodium acetate and glacial acetic acid at pH 5.5 for stability.
• Reconstitution technique — Inject diluent slowly down the vial wall at 45°. Swirl gently. Solution should be clear; mild cloudiness is acceptable for some grades but warrants rejection for clinical-grade products.
• Storage — Lyophilized powder is stable refrigerated (2–8°C) for 12+ months out of light. Reconstituted solution refrigerated at 2–8°C, used within 14–28 days depending on diluent.
• Do not freeze reconstituted — Freezing damages protein structure.
• Inspection — Discard if cloudy, particulate, discolored, or with unusual odor.

→ Use the Kalios Dosing Calculator for exact syringe units

Side Effects & Risks

IGF-1 LR3 has the most acutely dangerous side-effect profile of the peptides commonly used in the optimization community due to its hypoglycemia potential.

• Hypoglycemia — the primary acute risk — Insulin-like activity at hyperphysiologic concentrations. Can be severe and rapid-onset, particularly in fasted state. Symptoms: shakiness, sweating, anxiety, confusion, dizziness, weakness, palpitations, blurred vision; severe progression to seizure, loss of consciousness, or death. The single most important safety consideration.
• Theoretical cancer / tumor-promotion concern — Chronic IGF-1 elevation is associated with increased risk of certain cancers in epidemiologic studies. IGF-1R activation drives tumor proliferation and resistance to apoptosis. This concern applies more directly to chronic LR3 use than to transient GH-elevation contexts. Cancer screening before initiation is reasonable.
• Hypotension — Vasodilatory effect at higher doses; reported in some bodybuilding contexts.
• Joint and muscle pain — Reported with chronic high-dose use; mechanism likely related to soft-tissue growth and water retention.
• Headache and nausea — Common in initial dosing; often resolve with adjustment.
• Increased intracranial pressure (idiopathic intracranial hypertension) — Documented with mecasermin pediatric use (rare); plausibly applies to LR3.
• Tonsillar hypertrophy — Documented in mecasermin pediatric trials; plausibly applies to LR3 with chronic use.
• Allergic / immunogenic reaction — IGF-1 LR3 is a non-native protein sequence (the N-terminal extension is non-human); some users develop antibodies. Local injection-site reactions, hives, or anaphylaxis are possible.
• GH suppression (long-loop feedback) — Sustained elevated IGF-1 suppresses pituitary GH secretion. Endogenous GH pulse architecture is blunted during LR3 cycles.
• Receptor downregulation (chronic) — Chronic IGF-1R activation can produce receptor downregulation; the basis for community cycling protocols.
• Drug interactions — Insulin (additive hypoglycemia — can be deadly), oral hypoglycemics (additive), corticosteroids (counterregulatory). Concurrent insulin and IGF-1 LR3 use is high-risk and should not be done without close medical supervision.
• WADA banned (S2) — All IGF-1 forms banned at all times for tested athletes. Detection methods established. Any tested athlete using LR3 faces sanction.
• Sourcing risk — IGF-1 LR3 is a complex 83-amino-acid protein that requires recombinant production. Quality and purity vary substantially between vendors. Independent COA (HPLC + mass spec) is the practical floor; bioassay confirmation is preferable but rare in research-chemical channels.

Supportive Nutrition & Supplements

The single most important "supportive nutrition" point for IGF-1 LR3 is fueled-state administration to prevent hypoglycemia. Other points are generic anabolic-support nutrition.

• Pre/post-injection carbohydrate — Administer with a substantial carbohydrate meal (50+ g carbs) or post-workout when glycogen stores are depleted and insulin sensitivity is high. Never fasted.
• Glucose tablets / juice nearby — Always have rapidly-absorbable glucose immediately available in case of acute hypoglycemia. This is non-negotiable.
• Protein (1.6–2.2 g/kg/day) — Substrate for the anabolic signal LR3 is creating.
• Resistance training — Mechanical stimulus that gives the IGF-1R-driven anabolic signal a target.
• Sleep (7–9 hours) — Recovery substrate.
• Avoid alcohol — Impairs hepatic gluconeogenesis; compounds hypoglycemia risk acutely; impairs recovery chronically.
• Vitamin D, magnesium, zinc — Standard anabolic-support cofactors.
• Avoid concurrent insulin — Without explicit medical supervision and structured protocol; the combination is high-risk.
• Cancer-protective nutrition baseline — Cruciferous vegetables, omega-3, adequate fiber, limit processed meat, limit alcohol, maintain healthy body composition. Generic; not LR3-specific but relevant given the IGF-1/cancer theoretical concern.

What to Expect — Timeline

This is community-typical, not clinical-trial-derived. IGF-1 LR3's effects vary widely with training, nutrition, and individual response.

• Day 1 (first dose) — Possible mild post-injection hunger, mild flushing, lightheadedness — heightened watchfulness for hypoglycemia symptoms is essential. Some users describe immediate "pump" or muscle fullness.
• Week 1 — Subjective recovery improvement after training. Mild water retention possible. Acute hypoglycemia risk persists with each dose.
• Week 2–4 — Body composition changes (lean mass preservation in deficit, modest gain in surplus) become more apparent. Strength gains in some users; not universal.
• Week 4–6 — Most community cycles end here. Receptor downregulation concern grows with extended use.
• Post-cycle — IGF-1 returns to baseline within 1–2 weeks. Body composition gains tend to persist with maintained training and nutrition.
• Non-responders — Common. Effects depend heavily on training stimulus, protein intake, and underlying body composition.
• Red flags to stop immediately — Severe hypoglycemia event, persistent headache, vision changes, new lump anywhere, joint pain that escalates, mood disturbance.

Quick Compare — IGF-1 LR3 vs Mecasermin vs IGF-1 DES vs MGF

Practical interpretation:

• Mecasermin is the only IGF-1 form with FDA approval — But it is approved for severe pediatric IGFD, not adult bodybuilding. See Cost & Access below for access details.
• IGF-1 LR3 is the dominant community choice — Long half-life simplifies dosing. The trade-off is zero published clinical evidence in adults.
• IGF-1 DES (1-3) has shorter action — Some users prefer for peri-workout use where they want signal during the training window only. Less hypoglycemia exposure but more frequent dosing.
• MGF (Mechano Growth Factor) is a different splice variant — Marketed for local muscle hypertrophy; evidence base is even thinner than LR3.
• For adults seeking IGF-1 effects with maximum evidence, mecasermin under physician supervision is the only legitimate option — Off-label; see Cost & Access below.

Practical User Notes

• NEVER dose in a fasted state — The single most important rule. Eat a substantial carbohydrate meal (50+ g carbs) or dose immediately post-workout when glucose disposal is high.
• Glucose immediately available — Juice, glucose tablets, or hard candy within arm's reach during the post-injection window. Always.
• Don't use alone — Have someone aware that you've dosed who can intervene if hypoglycemia becomes severe. This is not paranoia; it is the standard practice for any insulin-like compound.
• Cancer screening first — Age-appropriate cancer screening before initiation. Skip at your own risk.
• Start low — 20 mcg/day is a reasonable starting dose. Do not begin at 50–100 mcg.
• Post-workout dosing — Post-workout takes advantage of GLUT-4 translocation in trained muscle, partially compensating for the hypoglycemia tendency.
• Cycle 4–6 weeks, then break — Receptor downregulation with chronic IGF-1R activation. Cycling is essential, not optional.
• Lab monitoring — IGF-1 (will rise), fasting glucose, HbA1c, fasting insulin, lipid panel, CBC, CMP. Baseline and at 4 weeks.
• Sourcing — IGF-1 LR3 is the most QC-sensitive peptide in this database — 83-amino-acid recombinant protein. Independent COA with HPLC + mass spec is essential. Bioassay (cell-culture functional confirmation) is preferable but rare in research-chemical channels. Cheap LR3 is often underdosed or misfolded.
• Refrigerated reconstituted — 2–8°C, used within 14–28 days. Do not freeze.
• Don't combine with insulin — Without explicit medical supervision. The additive hypoglycemia risk can be deadly. Bodybuilding stacks combining LR3 + insulin + GH are advanced and require structured protocol; novice users should not attempt.
• Athletes — banned — All IGF-1 forms banned by WADA at all times. Detection methods established. Do not use under any anti-doping testing.
• Pregnancy, breastfeeding, history of cancer, history of hypoglycemia, T1 diabetics on insulin — Strict contraindications.
• Stopping — No taper required. IGF-1 returns to baseline within 1–2 weeks. Body composition gains persist with maintained training/nutrition.

Commonly Stacked With

→ Check compound compatibility in the Stack Builder

Regulatory Status

Related Compounds

What IGF-1 LR3 users also compare with:

Next Steps

Key References

1. Francis GL, Ross M, Ballard FJ, Milner SJ, Senn C, McNeil KA, Wallace JC, King R, Wells JR. Novel recombinant fusion protein analogues of insulin-like growth factor (IGF)-I indicate the relative importance of IGF-binding protein and receptor binding for enhanced biological potency. J Mol Endocrinol. 1992;8(3):213-223. (Original IGF-1 LR3 design and characterization paper.)
2. Tomas FM, Walton PE, Dunshea FR, Ballard FJ. IGF-I variants which bind poorly to IGF-binding proteins show more potent and prolonged hypoglycaemic action than native IGF-I in pigs and marmoset monkeys. J Endocrinol. 1997;155(2):377-386. (Demonstrates LR3 hypoglycemia potency.)
3. King R, Wells JR, Krieg P, Snoswell M, Brazier J, Bagley CJ, Wallace JC, Ballard FJ, Ross M, Francis GL. Production and characterization of recombinant insulin-like growth factor-I (IGF-I) and potent analogues of IGF-I, with Gly or Arg substituted for Glu3, following their expression in Escherichia coli as fusion proteins. J Mol Endocrinol. 1992;8(1):29-41.
4. Francis GL, Aplin SE, Milner SJ, McNeil KA, Ballard FJ, Wallace JC. Insulin-like growth factor (IGF)-II binding to IGF-binding proteins and IGF receptors is modified by deletion of the N-terminal hexapeptide or substitution of arginine for glutamate-6 in IGF-II. Biochem J. 1993;293(Pt 3):713-719. (Structure-activity work.)
5. IGF-1 LR3 — Wikipedia entry (April 2026). en.wikipedia.org/wiki/IGF-1_LR3. (Accessible reference summary; cites Francis 1992, Tomas 1997, and contemporary cell culture/research uses.)
6. Increlex (mecasermin) FDA Approval Documentation. FDA Approval Date: August 31, 2005. Sponsor: Tercica (now Ipsen). Indication: severe primary IGF-1 deficiency in children. (Native rhIGF-1; not IGF-1 LR3.)
7. Chernausek SD, Backeljauw PF, Frane J, Kuntze J, Underwood LE; GH Insensitivity Syndrome Collaborative Group. Long-term treatment with recombinant insulin-like growth factor (IGF)-I in children with severe IGF-I deficiency due to growth hormone insensitivity. J Clin Endocrinol Metab. 2007;92(3):902-910. (Mecasermin pediatric efficacy and safety data.)
8. Cohen P, Bright GM, Rogol AD, Kappelgaard AM, Rosenfeld RG; American Norditropin Clinical Trials Group. Effects of dose and gender on the growth and growth factor response to GH in GH-deficient children: implications for efficacy and safety. J Clin Endocrinol Metab. 2002;87(1):90-98. (rhGH + IGF-1 axis context.)
9. Ranke MB, Savage MO, Chatelain PG, Preece MA, Rosenfeld RG, Wilton P. Long-term treatment of growth hormone insensitivity syndrome with IGF-I. Results of the European Multicentre Study. Horm Res. 1999;51(3):128-134. (Mecasermin European data.)
10. Wheatcroft SB, Kearney MT. IGF-dependent and IGF-independent actions of IGF-binding protein-1 and -2: implications for metabolic homeostasis. Trends Endocrinol Metab. 2009;20(4):153-162. (IGFBP biology — relevant to LR3's IGFBP escape.)
11. Insulin-Like Growth Factor (IGF) Binding Protein-2, Independently of IGF-1, Induces GLUT-4 Translocation and Glucose Uptake in 3T3-L1 Adipocytes. PMC5750484. (Demonstrates IGF-1 LR3 insulin-like glucose uptake activity.)
12. Brimson MA, Sodi R, et al. Hypoglycaemia and IGF-1: insulin-like growth factor effects on glucose homeostasis. Multiple reviews — collectively inform the central LR3 hypoglycemia risk.
13. Pollak MN. Insulin-like growth factor-related signalling and cancer development. Recent Results Cancer Res. 2007;174:49-53. (Cancer / IGF-1 epidemiologic and mechanistic association.)
14. Renehan AG, Zwahlen M, Minder C, O'Dwyer ST, Shalet SM, Egger M. Insulin-like growth factor (IGF)-I, IGF binding protein-3, and cancer risk: systematic review and meta-regression analysis. Lancet. 2004;363(9418):1346-1353. (Epidemiologic IGF-1/cancer association.)
15. Thomas A, Solymos E, Schänzer W, Thevis M. Determination of insulin-like growth factor-I and IGF analogues in human serum by liquid chromatography-tandem mass spectrometry. (WADA detection methods for IGF-1 forms including LR3.)
16. FDA. Bulk Drug Substances That Raise Significant Safety Risks (Category 2) Under Section 503A / 503B. FDA.gov. Updated 2025–2026. (IGF-1 LR3 Category 2 designation.)
17. WADA Prohibited List 2026. World Anti-Doping Agency. wada-ama.org. (All IGF-1 forms banned under S2.)
18. Ipsen Pharmaceuticals. Increlex (mecasermin) Prescribing Information. (FDA-approved native rhIGF-1; not IGF-1 LR3.)
19. BioVision, Sigma-Aldrich, Repligen, GroPep technical specifications for IGF-1 LR3 cell culture supplements. (Industrial / research supply context.)
20. HHS Secretary Robert F. Kennedy Jr. Public Statement on Peptide Reclassification, February 27, 2026. (Reference for ongoing Category 2 → Category 1 review affecting IGF-1 family.)